𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Phase I trial of irinotecan plus temozolomide in adults with recurrent malignant glioma

✍ Scribed by David A. Reardon; Jennifer A. Quinn; Jeremy N. Rich; Annick Desjardins; James Vredenburgh; Sridharan Gururangan; Sith Sathornsumetee; Michael Badruddoja; Roger McLendon; James Provenzale; James E. Herndon II; Jeannette M. Dowell; Jill L. Burkart; Herbert B. Newton; Allan H. Friedman; Henry S. Friedman

Publisher
John Wiley and Sons
Year
2005
Tongue
English
Weight
158 KB
Volume
104
Category
Article
ISSN
0008-543X

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Phase II trial of irinotecan plus celeco
Phase II trial of irinotecan plus celecoxib in adults with recurrent malignant glioma
✍ David A. Reardon; Jennifer A. Quinn; James Vredenburgh; Jeremy N. Rich; Sridhara πŸ“‚ Article πŸ“… 2005 πŸ› John Wiley and Sons 🌐 English βš– 219 KB

## Abstract ## BACKGROUND In the current study, the authors report a Phase II trial of irinotecan (CPT‐11), a topoisomerase I inhibitor active against malignant glioma (MG), with celecoxib, a selective COX‐2 inhibitor, among MG patients with recurrent disease. ## METHODS Patients with MG at any

Phase I study of temozolomide and escala
Phase I study of temozolomide and escalating doses of oral etoposide for adults with recurrent malignant glioma
✍ David N. Korones; Michal Benita-Weiss; Thomas E. Coyle; Laszlo Mechtler; Peter B πŸ“‚ Article πŸ“… 2003 πŸ› John Wiley and Sons 🌐 English βš– 74 KB

## Abstract ## BACKGROUND Although temozolomide is active against recurrent malignant glioma, responses in many patients are modest and short‐lived. Temozolomide may prove more effective in combination with other agents. Therefore, combination oral chemotherapy for these patients is a particularly